Abeona Q2 FY26 net loss widens to $20.2 million; revenue rises 31% Q/Q to $11.4 million
ABEO•Quarterly results and revenue
Abeona Therapeutics posted Q2 net loss of $20.2 million, or $0.35 a share, versus a $17.1 million loss in Q1.
Net ZEVASKYN revenue rose 31% quarter-over-quarter to $11.4 million, with revenue recognized for four of five treatments.
Cash position and treatment activity
Cash, cash equivalents and short-term investments totaled $146.8 million at June 30, down from $191.4 million at year-end.
ZEVASKYN treatments reached 12 since launch; three additional treatments were completed in Q3 to date.
CMS reimbursement update and management commentary
CMS granted ZEVASKYN NTAP status effective Oct. 1; CEO Vish Seshadri cited growing adoption as real-world experience matures.
Related News
Brief-Qtrex Quantum Ltd In Discussions With A US Department Of Defense’s Research Laboratory To Establish A Joint Quantum Development Program
QTEX•
Aspire Biopharma to present at Sidoti Micro-Cap Virtual Investor Conference
ASBP•
